Key result
Rhythm control strategies for subclinical and asymptomatic atrial fibrillation lack confirmed prognostic benefits in randomized trials, despite favorable observational data.
Why the study?
Randomized trials have failed to confirm observational benefits of catheter ablation over medical therapy, leaving unclear areas in treating subclinical and asymptomatic AF.
What is the current evidence regarding the treatment of subclinical and asymptomatic atrial fibrillation, and what are the potential benefits of rhythm control therapy?
What is the current evidence regarding the treatment of subclinical and asymptomatic atrial fibrillation, and what are the potential benefits of rhythm control therapy?
This review highlights the discrepancy between observational data and randomized trials regarding the benefits of rhythm control and catheter ablation in asymptomatic and subclinical atrial fibrillation.
Atrial Fibrillation (AF) may be diagnosed due to symptoms, or it may be found as an incidental electrocardiogram (ECG) finding, or by implanted devices recordings in asymptomatic patients. While anticoagulation, according to individual risk profile, has proven definitely beneficial in terms of prognosis, rhythm control strategies only demonstrated consistent benefits in terms of quality of life. In fact, evidence collected by observational data showed significant benefits in terms of mortality, stroke incidence, and prevention of cognitive impairment for patients referred to AF catheter ablation compared to those medically treated, however randomized trials failed to confirm such results. The aims of this review are to summarize current evidence regarding the treatment specifically of subclinical and asymptomatic AF, to discuss potential benefits of rhythm control therapy, and to highlight unclear areas.
No takes yet. Share an insight, caveat, or question.
Ballatore et al. (2019) conducted a review in Subclinical and asymptomatic Atrial Fibrillation. Rhythm control therapy was evaluated. Rhythm control strategies for subclinical and asymptomatic atrial fibrillation lack confirmed prognostic benefits in randomized trials, despite favorable observational data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: